Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745187 | 0.78 | BRD9 (0.36) | BRD9ACHE | |
| SCHEMBL5357007 | 0.75 | HTT (0.41) | DRD2DRD4NOTUMPARP1ACHE | |
| SCHEMBL7872035 | 0.69 | NOTUM (0.44) | NOTUMPARP1 | |
| SCHEMBL9382215 | 0.69 | DRD2 (0.31) | DRD2DRD4NOTUM | |
| SCHEMBL5865674 | 0.69 | KDM4E (0.42) | DRD2 | |
| SCHEMBL25786097 | 0.67 | MAPT (0.49) | DRD4NOTUMPARP1 | |
| SCHEMBL9180877 | 0.66 | DRD2 (0.44) | DRD2DRD4NOTUMPARP1ACHE | |
| SCHEMBL5369195 | 0.66 | PRKD1 (0.42) | PARP1 | |
| SCHEMBL5655667 | 0.66 | NOTUM (0.41) | NOTUMBRD9PARP1 | |
| SCHEMBL13349977 | 0.65 | PARP1 (0.40) | DRD2DRD4NOTUMPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214685-B2 | Prodrugs for a selective cancer therapy | Tietze, Lutz F. (DE) | 2007-05-08 | — | — | US | claimed |
| EP-1280771-B1 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | TIETZE LUTZ F PROF DR (DE) | 2004-10-13 | — | — | EP | claimed |
| US-20040033962-A1 | Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy | TIETZE, LUTZ F. (DE) | 2004-02-19 | — | — | US | claimed |
| EP-1280771-A2 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | Tietze, Lutz F., Prof. Dr. (DE) | 2003-02-05 | — | — | EP | claimed |
| WO-2001083448-A2 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | TIETZE LUTZ F (DE) | 2001-11-08 | — | — | WO | claimed |
| EP-2173739-B1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA BV (NL) | 2013-07-31 | — | — | EP | disclosed |
| US-7214685-B2 | Prodrugs for a selective cancer therapy | Tietze, Lutz F. (DE) | 2007-05-08 | — | — | US | disclosed |
| EP-1280771-B1 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | TIETZE LUTZ F PROF DR (DE) | 2004-10-13 | — | — | EP | disclosed |
| EP-1280771-B1 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | TIETZE LUTZ F PROF DR (DE) | 2004-10-13 | — | — | EP | disclosed |
| US-20040033962-A1 | Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy | TIETZE, LUTZ F. (DE) | 2004-02-19 | — | — | US | disclosed |
| US-20040033962-A1 | Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy | TIETZE, LUTZ F. (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1280771-A2 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | Tietze, Lutz F., Prof. Dr. (DE) | 2003-02-05 | — | — | EP | disclosed |
| EP-1280771-A2 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | Tietze, Lutz F., Prof. Dr. (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083448-A3 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | TIETZE LUTZ F (DE) | 2002-06-20 | — | — | WO | disclosed |
| WO-2001083448-A3 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | TIETZE LUTZ F (DE) | 2002-06-20 | — | — | WO | disclosed |
| WO-2001083448-A2 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | TIETZE LUTZ F (DE) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001083448-A2 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | TIETZE LUTZ F (DE) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001083448-A2 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | TIETZE LUTZ F (DE) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033962-A1 | Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy | DHPS, DERA, DUT | DRD2 706/4885DRD4 1272/4885NOTUM 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.